2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - 388-390
Technology and Procedures, Omics Technologies, Bioinformatics, Computational Biology, Treatment Considerations, Drug Development, Biological Therapies, Transplantation, Checkpoint Inhibitor, Immunotherapy, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Pathogenesis, CHIP, Hematopoiesis, Immune Mechanism, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Study Population, Human, Adult
PAPER

713 A phase I study of decoy resistant IL-18 in patients in relapse after allogeneic stem cell transplantation

Elizabeth Florence Krakow, MD,CM, MSc, Jacob Appelbaum, MD/PhD2, Julie R Boiko, MD, PhD, MS3, Laura S Connelly-Smith, MBBCh4, Catherine J Lee, MD, MS5, Dow Dunbar6, Mary Jaenicke7, Elizabeth Frecker8, Nicole Vartanian9, Geoff R Hill, MD10
1 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
2 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
3 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States, Seattle Children's Hospital, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
4 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
5 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
6 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States
7 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
8 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
9 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
10 Fred Hutchinson Cancer Research Center, Seattle, Washington, United States, University of Washington, Seattle, Washington, United States

Introduction:  Relapse represents the major limitation of allogeneic stem cell transplantation (alloSCT). Immune escape from graft-versus-leukemia (GVL) is associated with downregulation of MHC class II and antigen processing, a process reversible following interferon-gamma (IFNγ) exposure. Interleukin-18 (IL-18) is a master cytokine controlling IFNγ secretion but is rapidly inactivated in vivo by IL-18 binding protein (IL-18BP). Decoy-resistant IL-18 (DR-18; ST-067) is resistant to IL-18BP, has prolonged activity in vivo (Zhou T et al, Nature 2020), and prevents relapse after alloSCT in preclinical systems (Minnie S et al, Sci Immunol, 2022). We hypothesized that DR-18 would generate an IFNγ response to enhance MHC II expression and antigen presentation, thereby inducing responses in patients relapsing after alloSCT. We report the first 8 patients treated on the DR. DREAM study (NCT06492707), a phase 1, open-label, dose-finding trial of weekly subcutaneous DR-18 after alloSCT.

Methods: Adults with persistent/recurrent AML or MDS after alloSCT received 4 weekly induction doses, a 2-week holiday, then up to 4 maintenance doses. Starting doses of 30 µg/kg (cohort 1) or 60 µg/kg (cohort 2) were assigned in cohorts of n = 1 per BOIN algorithm, with subsequent intra-patient dose escalation/de-escalation. Toxicity used CTCAE v5.0; response used ELN criteria. Cytokine analysis and single-cell RNA sequencing were performed.

Results: As of 06-2026, 8 patients with adverse AML/MDS genetic risk were treated (6 cohort 1, 2 cohort 2; median age 60 [27-76]; 4 female; 7 White, 1 Asian). They had received a median 3.5 (range 2-7) prior lines of treatment. Pre-DR-18, malignant blasts ranged from 0.03% to 46%. Following DR-18, cytokine release syndrome (CRS) occurred in 6 patients (grade 1 n= 5 events/4 patients; grade 2 n=4 events/1 patient; grade 3 n=1) at doses of 15 to 90 µg/kg. Two patients/3 CRS events required tocilizumab/dexamethasone. One patient with grade 3 CRS after dose #3 (60 µg/kg) required inotrope support with concurrent development of hemophagocytic lymphohistiocytosis (HLH) manifesting as cytopenias, marrow hypoplasia with hemophagocytosis, acute kidney injury, and markedly elevated ferritin (437,532 ng/mL), sIL-2R (19999 pg/mL) and CXCL9 (233,000 pg/ml, normal < 121). She was additionally treated with anakinra and ruxolitinib with complete resolution over 18 days. LFT elevations were mostly mild (max grade 1 n = 2 patients; grade 2 n=3; grade 3 n=1). No patients developed ICANS or confirmed GVHD. There were 2 dose limiting toxicities, grade 3 transaminitis and HLH developing within hours of dose #5 = 90 µg/kg and dose #3 = 60 µg/kg, respectively. Tolerability was no different in minimal residual disease (MRD) vs. high blast burden settings. The study is ongoing, but the maximum tolerated dose post alloSCT is likely 30-60 µg/kg.

Three patients with MRD-only relapses achieved MRD-negative complete remission which, in the longest case (the patient with HLH), has been sustained >8 months. No responses were seen in overt morphological relapse. Responders began DR-18 at median 92 days (71-213) after HCT vs. 15 months (14-54.5) for non-responders.

DR-18 generated robust, on-target immune activation: serum IL-18 and the IFNγ-induced chemokine CXCL9 rose 1-2 logs after dose 1 and dose 4 (both p<0.05; CXCL9 to ~5,000-10,000 pg/mL), confirming engagement of the IFNγ axis. Blood single-cell RNA sequencing demonstrated induction of STAT1/IFNγ signaling and T-cell activation after DR-18 with significantly upregulated IFNγ response genes (STAT1, GBP5, ISG20, MT2A) in CD4 and CD8 memory subsets (p<0.0001). A population of activated NK-like CD8 T cells markedly expanded after dosing and upregulated IFNγ, antigen presentation and cytolytic programs (e.g., STAT1, CD74, numerous HLA class II genes, GZMB, PRF1).  Among non-responders, leukemic cells likewise upregulated IFNγ response but did not display increased antigen presentation-related gene expression.

Conclusions: This is the first study of exogenous DR-18 administration for hematological malignancies relapsing after alloSCT, demonstrating systemic immune activation associated with CRS. Anti-leukemic efficacy was seen in patients treated early after alloSCT with low disease burden. This study also provides the first direct evidence that IL-18 can induce HLH, raising caution in chimeric antigen receptor T cell settings where IL-18 armoring may induce irreversible IL-18 dysregulation.

Elizabeth Florence Krakow, MD,CM, MSc: Simcha Therapeutics - Research Funding; Promicell, Inc - Research Funding